Colorectal cancer vaccine trial halted after survival imbalance
TL;DR Summary
BioNTech and Genentech terminated a phase 2 trial of autogene cevumeran (BNT122) in surgically resected stage II–III colorectal cancer after an independent safety board identified a numerical imbalance in overall survival favoring the observation group; the decision underscores the challenges of using personalized mRNA vaccines as monotherapy in immunotherapy-resistant tumors, though a separate BNT122 trial in combination with immunotherapy remains ongoing. BioNTech’s stock fell about 7.5% on the news, while Moderna advanced after a related phase 3 win.
Topics:business#biotech#cancer#clinical-trial#colorectal-cancer#healthcare#mrna#note-only-five-allowed
- BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test Fierce Biotech
- BioNTech halts mRNA colorectal cancer vaccine trial after safety review Reuters
- BioNTech, Roche Scrap Cancer Vaccine Trial in Blow to Field Bloomberg.com
- BioNTech to terminate mid-stage trial of mRNA cancer vaccine Yahoo Finance
- Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) Seeking Alpha
Reading Insights
Total Reads
1
Unique Readers
8
Time Saved
2 min
vs 3 min read
Condensed
83%
450 → 78 words
Want the full story? Read the original article
Read on Fierce Biotech